Pharma

Your Article Summary

See Latest Articles

Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR (triptorelin pamoate) NDA from US FDA
Watson Pharmaceuticals, 07/15/09

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it received a Complete Response Letter from the U.S. Food and Drug Administration on its New Drug Application for TRELSTAR 22.5 mg, a 24-week formulation of TRELSTAR for the palliative treatment of advanced prostate cancer. The TRELSTAR NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09

Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09

Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09

 See all of Regulatory Issues